...
search icon
phar-img

Pharming Group NV, Common Stock

PHAR

NMQ

$10.265

+$0.26

(2.6%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$598.44M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.31K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.44
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.65 L
$11.07 H
$10.265

About Pharming Group NV, Common Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePHARSectorS&P500
1-Week Return14.4%-1.83%1.17%
1-Month Return27.68%0.87%13.71%
3-Month Return14.09%-8.31%-6.62%
6-Month Return22.52%-10.68%-5.57%
1-Year Return5.37%-5.59%9.24%
3-Year Return35.27%6.11%41.93%
5-Year Return-40.06%34.94%93.22%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue228.39M189.85M205.62M245.32M286.89M[{"date":"2020-12-31","value":79.61,"profit":true},{"date":"2021-12-31","value":66.18,"profit":true},{"date":"2022-12-31","value":71.67,"profit":true},{"date":"2023-12-31","value":85.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue25.34M20.18M17.56M25.21M34.17M[{"date":"2020-12-31","value":74.15,"profit":true},{"date":"2021-12-31","value":59.07,"profit":true},{"date":"2022-12-31","value":51.39,"profit":true},{"date":"2023-12-31","value":73.78,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit203.06M169.67M188.06M220.10M252.72M[{"date":"2020-12-31","value":80.35,"profit":true},{"date":"2021-12-31","value":67.14,"profit":true},{"date":"2022-12-31","value":74.42,"profit":true},{"date":"2023-12-31","value":87.1,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin88.91%89.37%91.46%89.72%88.09%[{"date":"2020-12-31","value":97.21,"profit":true},{"date":"2021-12-31","value":97.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.1,"profit":true},{"date":"2024-12-31","value":96.32,"profit":true}]
Operating Expenses120.97M156.72M169.83M225.49M261.04M[{"date":"2020-12-31","value":46.34,"profit":true},{"date":"2021-12-31","value":60.04,"profit":true},{"date":"2022-12-31","value":65.06,"profit":true},{"date":"2023-12-31","value":86.38,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income82.09M27.84M18.23M(4.88M)(8.32M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":33.91,"profit":true},{"date":"2022-12-31","value":22.21,"profit":true},{"date":"2023-12-31","value":-5.94,"profit":false},{"date":"2024-12-31","value":-10.14,"profit":false}]
Total Non-Operating Income/Expense(22.97M)2.58M(4.22M)(9.57M)(4.98M)[{"date":"2020-12-31","value":-889.64,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-163.6,"profit":false},{"date":"2023-12-31","value":-370.55,"profit":false},{"date":"2024-12-31","value":-192.94,"profit":false}]
Pre-Tax Income47.47M22.03M14.99M(12.01M)(8.22M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":46.42,"profit":true},{"date":"2022-12-31","value":31.57,"profit":true},{"date":"2023-12-31","value":-25.31,"profit":false},{"date":"2024-12-31","value":-17.31,"profit":false}]
Income Taxes6.83M6.76M1.31M(1.46M)2.43M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":19.21,"profit":true},{"date":"2023-12-31","value":-21.42,"profit":false},{"date":"2024-12-31","value":35.51,"profit":true}]
Income After Taxes40.63M15.27M13.67M(10.55M)(10.64M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.59,"profit":true},{"date":"2022-12-31","value":33.65,"profit":true},{"date":"2023-12-31","value":-25.96,"profit":false},{"date":"2024-12-31","value":-26.2,"profit":false}]
Income From Continuous Operations33.03M13.49M13.67M(10.55M)(11.84M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":40.83,"profit":true},{"date":"2022-12-31","value":41.39,"profit":true},{"date":"2023-12-31","value":-31.93,"profit":false},{"date":"2024-12-31","value":-35.84,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income37.75M16.00M13.67M(10.55M)(10.64M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":42.38,"profit":true},{"date":"2022-12-31","value":36.23,"profit":true},{"date":"2023-12-31","value":-27.94,"profit":false},{"date":"2024-12-31","value":-28.2,"profit":false}]
EPS (Diluted)0.160.220.46(0.20)(0.21)[{"date":"2020-12-31","value":33.74,"profit":true},{"date":"2021-12-31","value":48.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-42.52,"profit":false},{"date":"2024-12-31","value":-46.33,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PHAR
Cash Ratio 2.27
Current Ratio 3.77
Quick Ratio 3.02

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PHAR
ROA (LTM) -0.52%
ROE (LTM) -5.38%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PHAR
Debt Ratio Lower is generally better. Negative is bad. 0.45
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.55

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PHAR
Trailing PE NM
Forward PE 169.49
P/S (TTM) 2.16
P/B 2.90
Price/FCF 70
EV/R 1.87
EV/Ebitda 34.07

FAQs

What is Pharming Group NV share price today?

Pharming Group NV (PHAR) share price today is $10.265

Can Indians buy Pharming Group NV shares?

Yes, Indians can buy shares of Pharming Group NV (PHAR) on Vested. To buy Pharming Group NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PHAR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pharming Group NV be purchased?

Yes, you can purchase fractional shares of Pharming Group NV (PHAR) via the Vested app. You can start investing in Pharming Group NV (PHAR) with a minimum investment of $1.

How to invest in Pharming Group NV shares from India?

You can invest in shares of Pharming Group NV (PHAR) via Vested in three simple steps:

  • Click on Sign Up or Invest in PHAR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pharming Group NV shares
What is Pharming Group NV 52-week high and low stock price?

The 52-week high price of Pharming Group NV (PHAR) is $11.07. The 52-week low price of Pharming Group NV (PHAR) is $6.65.

What is Pharming Group NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pharming Group NV (PHAR) is 2.90

What is the Market Cap of Pharming Group NV?

The market capitalization of Pharming Group NV (PHAR) is $598.44M

What is Pharming Group NV’s stock symbol?

The stock symbol (or ticker) of Pharming Group NV is PHAR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top